Browse > Article
http://dx.doi.org/10.5483/BMBRep.2014.47.7.195

Antiplatelet and antithrombotic activities of purpurogallin in vitro and in vivo  

Ku, Sae-Kwang (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University)
Bae, Jong-Sup (College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Publication Information
BMB Reports / v.47, no.7, 2014 , pp. 376-381 More about this Journal
Abstract
Enzymatic oxidation of pyrogallol was efficiently transformed to an oxidative product, purpurogallin (PPG). Here, the anticoagulant activities of PPG were examined by monitoring activated partial thromboplastin time (aPTT), prothrombin time (PT), and the activities of thrombin and activated factor X (FXa). And, the effects of PPG on expression of plasminogen activator inhibitor type 1 (PAI-1) and tissue-type plasminogen activator (t-PA) were evaluated in tumor necrosis factor (TNF)-${\alpha}$ activated human umbilical vein endothelial cells (HUVECs). Treatment with PPG resulted in prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, as well as inhibited production of thrombin and FXa in HUVECs. In addition, PPG inhibited thrombin-catalyzed fibrin polymerization and platelet aggregation. PPG also elicited anticoagulant effects in mice. In addition, treatment with PPG resulted in significant reduction of the PAI-1 to t-PA ratio. Collectively, PPG possesses antithrombotic activities and offers a basis for development of a novel anticoagulant.
Keywords
Coagulation cascade; Endothelium; Fibrinolysis; Purpurogallin;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Davie, E. W. (1995) Biochemical and molecular aspects of the coagulation cascade. Thromb. Haemost. 74, 1-6.
2 Hoffman, M. M. and Monroe, D. M. (2005) Rethinking the coagulation cascade. Curr. Hematol. Rep. 4, 391-396.
3 Davie, E. W., Fujikawa, K. and Kisiel, W. (1991) The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 30, 10363-10370.   DOI   ScienceOn
4 Esmon, C. T. (2001) Role of coagulation inhibitors in inflammation. Thromb. Haemost. 86, 51-56.
5 Quinn, C., Hill, J. and Hassouna, H. (2000) A guide for diagnosis of patients with arterial and venous thrombosis. Clin. Lab. Sci. 13, 229-238.
6 Levi, M., Schultz, M. and van der Poll, T. (2011) Coagulation biomarkers in critically ill patients. Crit. Care Clin. 27, 281-297.   DOI   ScienceOn
7 Veser, J. (1987) Kinetics and inhibition studies of catechol O-methyltransferase from the yeast Candida tropicalis. J. Bacteriol. 169, 3696-3700.   DOI
8 Abou-Karam, M. and Shier, W. T. (1999) Inhibition of oncogene product enzyme activity as an approach to cancer chemoprevention. Tyrosine-specific protein kinase inhibition by purpurogallin from Quercus sp. nutgall. Phytother. Res. 13, 337-340.   DOI
9 Das, M., Bickers, D. R. and Mukhtar, H. (1984) Plant phenols as in vitro inhibitors of glutathione S-transferase(s). Biochem. Biophys. Res. Commun. 120, 427-433.   DOI   ScienceOn
10 Zeng, L. H. and Wu, T. W. (1992) Purpurogallin is a more powerful protector of kidney cells than Trolox and allopurinol. Biochem. Cell Biol. 70, 684-690.   DOI   ScienceOn
11 Wu, T. W., Zeng, L. H., Wu, J. and Carey, D. (1991) Purpurogallin--a natural and effective hepatoprotector in vitro and in vivo. Biochem. Cell Biol. 69, 747-750.   DOI   ScienceOn
12 Wu, T. W., Zeng, L. H., Wu, J., Fung, K. P., Weisel, R. D., Hempel, A. and Camerman, N. (1996) Molecular structure and antioxidant specificity of purpurogallin in three types of human cardiovascular cells. Biochem. Pharmacol. 52, 1073-1080.   DOI   ScienceOn
13 Kim, T. H., Ku, S. K., Lee, I. C. and Bae, J. S. (2012) Anti-inflammatory functions of purpurogallin in LPS-activated human endothelial cells. BMB Rep. 45, 200-205.   과학기술학회마을   DOI   ScienceOn
14 Esmon, C. T. (2005) The interactions between inflammation and coagulation. Br. J. Haematol. 131, 417-430.   DOI   ScienceOn
15 Sugo, T., Nakamikawa, C., Tanabe, S. and Matsuda, M. (1995) Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets. J. Biochem. 117, 244-250.   DOI   ScienceOn
16 Philip-Joet, F., Alessi, M. C., Philip-Joet, C., Aillaud, M., Barriere, J. R., Arnaud, A. and Juhan-Vague, I. (1995) Fibrinolytic and inflammatory processes in pleural effusions. Eur. Respir. J. 8, 1352-1356.   DOI   ScienceOn
17 Rao, L. V., Rapaport, S. I. and Lorenzi, M. (1988) Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 71, 791-796.
18 Ghosh, S., Ezban, M., Persson, E., Pendurthi, U., Hedner, U. and Rao, L. V. (2007) Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J. Thromb. Haemost. 5, 336-346.   DOI   ScienceOn
19 Lopez, S., Peiretti, F., Bonardo, B., Juhan-Vague, I. and Nalbone, G. (2000) Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152, 359-366.   DOI   ScienceOn
20 Schleef, R. R., Bevilacqua, M. P., Sawdey, M., Gimbrone, M. A., Jr. and Loskutoff, D. J. (1988) Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J. Biol. Chem. 263, 5797-5803.
21 Hamaguchi, E., Takamura, T., Shimizu, A. and Nagai, Y. (2003) Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. J. Pharmacol. Exp. Ther. 307, 987-994.   DOI   ScienceOn
22 Kim, T. H., Ku, S. K. and Bae, J. S. (2012) Antithrombotic and profibrinolytic activities of eckol and dieckol. J. Cell Biochem. 113, 2877-2883.   DOI   ScienceOn
23 Bae, J. S. (2011) Antithrombotic and profibrinolytic activities of phloroglucinol. Food Chem. Toxicol. 49, 1572-1577.   DOI   ScienceOn
24 Kim, S. Y., Kim, S., Kim, J. M., Jho, E. H., Park, S., Oh, D. and Yun-Choi, H. S. (2011) PKC inhibitors RO 31-8220 and Go 6983 enhance epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. BMB Rep. 44, 140-145.   과학기술학회마을   DOI   ScienceOn
25 Nowak, P., Zbikowska, H. M., Ponczek, M., Kolodziejczyk, J. and Wachowicz, B. (2007) Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thromb. Res. 121, 163-174.   DOI   ScienceOn
26 Bae, J. S. and Rezaie, A. R. (2008) Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost 100, 101-109.
27 Dejana, E., Callioni, A., Quintana, A. and de Gaetano, G. (1979) Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thromb. Res. 15, 191-197.   DOI   ScienceOn
28 Schouten, M., Wiersinga, W. J., Levi, M. and van der Poll, T. (2008) Inflammation, endothelium, and coagulation in sepsis. J. Leukoc. Biol. 83, 536-545.   DOI
29 Inamori, Y., Muro, C., Sajima, E., Katagiri, M., Okamoto, Y., Tanaka, H., Sakagami, Y. and Tsujibo, H. (1997) Biological activity of purpurogallin. Biosci. Biotechnol. Biochem. 61, 890-892.   DOI   ScienceOn